• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Hyperion Lowers Price, Adds Shares in $50M IPO

July 27, 2012
By Marie Powers
Orphan disease firm Hyperion Therapeutics Inc. priced its initial public offering (IPO), shaving the price from the midpoint of $12 per share cited in its amended S-1 filing earlier this month to $10 per share – $1 below the proposed range – but upsizing the offering from 4.2 million to 5 million shares.
Read More

Lew Bender: Career Detours Lead N.J. Boy to Biotech

July 26, 2012
By Marie Powers
Lew Bender, CEO of Interleukin Genetics Inc., of Waltham, Mass., never had a master plan to run a biotech company.
Read More

Eteplirsen Wows in DMD, Sarepta Shares Double

July 25, 2012
By Marie Powers
Sarepta Therapeutics Inc. (formerly AVI BioPharma Inc.) wowed clinicians and investors Tuesday with Phase IIb findings for its exon-skipping compound, eteplirsen, in Duchenne's muscular dystrophy (DMD).
Read More

Histogenics $49M Round to Advance NeoCart Implant

July 24, 2012
By Marie Powers
Regenerative medicine developer Histogenics Corp. said Tuesday that it completed a $49 million financing to complete its ongoing Phase III program for lead candidate NeoCart, an autologous neocartilage tissue implant that utilizes a patient's own cells to regenerate articular cartilage in the knee. The trial is currently enrolling patients.
Read More

Amicus, GSK Extend Their Fabry Disease Collaboration

July 19, 2012
By Marie Powers
Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.
Read More

Sign Path Pharma Sets Its Sights on Liposomal Curcumin

July 18, 2012
By Marie Powers
Scientists have long been fascinated by curcumin, a naturally occurring chemical found in the root of turmeric, a plant known as Curcuma longa. The compound is known to have antioxidant and anti-inflammatory properties, but traditional use has been limited to topical and gastrointestinal indications because oral bioavailability is negligible.
Read More

OSE Pharma Is Seeking to Revive Lung Cancer Vaccine

July 18, 2012
By Marie Powers
Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris.
Read More

HGSI, GSK Seal Deal, Settle on $14.25 per Share; $3.6B Value

July 17, 2012
By Marie Powers
After mulling its options for three months, Human Genome Sciences Inc. accepted a sweetened proposal from GlaxoSmithKline plc, agreeing to a union that most industry observers expected all along.
Read More

Celgene's Apremilast Looks Positive in Top-Line PsA Data

July 13, 2012
By Marie Powers
Celgene International Sàrl, the Boudry, Switzerland, subsidiary of Celgene Corp., reported positive top-line results for apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients with psoriatic arthritis (PsA) who had received an oral disease-modifying antirheumatic drug (DMARD) or biologic therapy or had failed on an anti-tumor necrosis factor (TNF) agent.
Read More

OSE Pharma Is Seeking to Revive Lung Cancer Vaccine

July 12, 2012
By Marie Powers
Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe